The ELAVL2 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the ELAVL2 gene in the human SK-HEP-1 host cell background. This gene-edited pool, generated via CRISPR/Cas9-mediated gene disruption, provides a loss-of-function model for investigating ELAVL2-dependent post-transcriptional gene regulation in a non-neuronal context. The polyclonal format preserves population-level diversity, enabling robust functional studies without clonal selection artifacts, and is well-suited for assays that require bulk cellular responses rather than monoclonal homogeneity.
The host cell line SK-HEP-1 is an established human liver adenocarcinoma cell line originally derived from the ascitic fluid of a male patient with liver adenocarcinoma. It exhibits an adherent epithelial morphology and is widely used as a model for hepatocarcinoma biology, drug metabolism, and tumor microenvironment studies. Although SK-HEP-1 cells have been annotated as endothelial-like in some contexts, they retain key characteristics of malignant hepatic cells, making them a versatile platform for cancer research, including investigations of metastasis, angiogenesis, and therapeutic resistance. Importantly, SK-HEP-1 cells lack endogenous expression of many neuronal markers, offering a clean background to study ectopic or aberrant ELAVL2 function.
ELAVL2 encodes an RNA-binding protein that specifically recognizes AU-rich elements (AREs) in the 3?? untranslated regions of target mRNAs, protecting them from decay and enhancing their translation. It functions downstream of neuronal differentiation signals, including the transcription factor NEUROD1, and is subject to auto-regulatory feedback. ELAVL2 interacts with other ELAV family members (HuC, HuD), ARE-binding proteins, RNA polymerase II, and splicing factors, forming an mRNA stabilization complex that includes translation initiation factors. Key downstream targets stabilized by ELAVL2 include GAP43 (neuromodulin), MAPT (tau), neurofilament mRNAs, and c-fos, linking its activity to neuronal development, synaptic plasticity, and immediate-early gene responses.
In the non-neuronal SK-HEP-1 context, ELAVL2 knockout provides a unique model to dissect the protein??s role in ectopic or cancer-associated settings. Given ELAVL2??s link to paraneoplastic neurological syndromes??where tumors express neuronal antigens??its disruption in a liver adenocarcinoma line enables investigation of aberrant RNA regulation in tumor biology. This model can be used to explore how ELAVL2 influences mRNA stability networks beyond the nervous system, potentially uncovering roles in cell proliferation, migration, or response to cellular stress, and it offers a platform to screen for small molecules that modulate ELAVL2 activity in cancerous environments.
Typical research applications include post-transcriptional gene regulation studies using techniques such as RNA immunoprecipitation (RIP) to capture ELAVL2-RNA interactions, luciferase reporter assays driven by ARE-containing 3??UTRs to measure mRNA stabilization, RT-qPCR to quantify changes in target transcript levels (e.g., GAP43, MAPT), and western blotting to assess ELAVL2 and downstream protein expression. Additionally, fluorescence microscopy can be employed to monitor subcellular localization of RNA-binding proteins. This knockout pool is ideal for functional validation of ELAVL2 targets, high-throughput screening of candidate therapeutics, and mechanistic dissection of mRNA decay pathways in a liver cancer model. For further details, please contact Ascent Research.
